|
Jul 5
|
The Best Stocks to Invest $1,000 In Right Now
|
|
Jul 4
|
Vertex reports long-term results for Casgevy in sickle cell and thalassaemia
|
|
Jul 2
|
Vertex Pharmaceuticals (NasdaqGS:VRTX) Secures EU Approval for New CF Treatment Access
|
|
Jul 2
|
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
|
|
Jul 2
|
Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold
|
|
Jul 1
|
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
|
|
Jun 30
|
AbbVie to buy Capstan for up to $2.1 billion in immunology push
|
|
Jun 30
|
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
|
|
Jun 29
|
H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results
|
|
Jun 27
|
Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug
|
|
Jun 26
|
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
|
|
Jun 20
|
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
|
|
Jun 20
|
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
|
|
Jun 20
|
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
|
|
Jun 19
|
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
|
|
Jun 19
|
2 Growth Stocks to Buy and Hold for 10 Years
|
|
Jun 16
|
Exploring High Growth Tech Stocks In The US This June 2025
|
|
Jun 16
|
3 Stocks Estimated To Be Trading At A Discount Of Up To 48.1%
|
|
Apr 25
|
CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?
|
|
Apr 24
|
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts
|